industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Posts Tagged ‘white paper’


Wednesday, November 2nd, 2011

New Scope of Reusable Medical Device Cleaning Validations is Examined in New White Paper from Microtest Laboratories

AGAWAM, MASS. – Nov. 2, 2011 – A new white paper detailing the new scope of reusable medical device cleaning validations is available free from Microtest Laboratories on the Web at http://www.microtestlabs.com/new-scope-cleaning-validation-paper.

“Cleaning validation for reusable medical devices is an important step in proving their safety. Available guidance documents now indicate that the traditional method of validating cleanliness, spore log reduction, will no longer be acceptable. Analytical assays capable of providing quantitative results will now be required instead,” writes white paper author Patrick Kenny, Manager of Analytical Services, Microtest Laboratories.

In the new white paper, “The New Scope of Reusable Medical Device Cleaning Validations,” Kenny notes that “although a new requirement for reusable medical devices, these tests are traditional analytical assays that are performed routinely on other types of samples.”

“An effective protocol and report that includes justifications for the test soil and assays chosen, as well as thorough documentation of all parameters used in the validation, will help ensure success for the device’s submission,” he notes.

In the paper, Kenny also discusses cleaning validation analytical assays as well as various methods and scenarios related to performing the validation. His recommendations are based on several key documents relating to reusable device cleaning validations that are either in draft or final form. They include AAMI document TIR30:2003, a comprehensive guide to medical device cleaning validations. TIR30 is currently in revision, and an updated version is scheduled for 2011 release.

Kenny holds a M.S. degree in Chemistry and has spent the past 13 years working in QC, R&D and manufacturing laboratories. At Microtest, Kenny leads the services group performing medical device and pharmaceutical analytical testing for companies worldwide.

Downloada free copy of the white paper, The New Scope of Reusable Medical Device Cleaning Validations,from the Microtest Laboratories website at http://www.microtestlabs.com/new-scope-cleaning-validation-paper.

Microtest’s broad portfolio of medical device and combination product testing services include sterilization validation, reusable device studies, endotoxin and sterility testing, and package validation.

About Microtest Laboratories

Microtest Laboratories is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, U.S.A., the company provides expertise and flexible processes that enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow Microtest Laboratories on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

Bookmark and Share

Monday, April 11th, 2011

New White Paper: “The Insider’s Guide to Applying Miniature Solenoid Valves,” from ASCO Valve

FLORHAM PARK, N.J. — April 11, 2011 — A new white paper, The Insider’s Guide to Applying Miniature Solenoid Valves, consolidates the expert views of designers and manufacturers to provide a step-by-step resource for applying miniature solenoid valves for myriad uses across multiple industries.

The paper is available to download from http://bit.ly/h0iq7f.

“Equipment designers frequently must incorporate miniature solenoid valves into their pneumatic designs. These valves are important components of medical devices and instrumentation as well as environmental, analytical, and similar product applications,” said white paper author Mike Elsigian, marketing manager, ASCO Valve, Inc.

In the white paper, Elsigian defines which requirements are critical for common applications. He details how the selection of miniature solenoid valves for the design of a given device usually involves finely balancing tradeoffs among competing pressures for reliability, service life, light weight, higher flow, optimized power use, standards compliance, and more.

Elsigian also highlights the introduction of newer valve technologies that can lessen or eliminate difficult compromises — while increasing performance. “New miniature solenoid valve technologies represent the fusion of several innovative approaches to meet the widest possible range of demands from knowledgeable designers across multiple industries,” he said.

“All too often, these designers find themselves frustrated as they face compromise after compromise. Pressure for increasingly miniaturized devices complicates every step of the design and valve selection process. And missteps can wreak havoc,” he said. “We’re hoping that the expertise we provide will assist designers in achieving the balance they need for success among the variety of often-contradictory performance requirements demanded by their applications.”

Download the new white paper, “The Insider’s Guide to Applying Miniature Solenoid Valves,” at http://bit.ly/h0iq7f.

Follow ASCO on Twitter at http://twitter.com/ascovalve. Find ASCO on Facebook at http://facebook.com/ascovalve.

Emerson Industrial Automation

Emerson Industrial Automation, a business of Emerson, delivers manufacturing solutions designed with leading technologies — including mechanical, electrical and ultrasonic — to provide the most advanced industrial automation possible for numerous and diverse industries worldwide. The company’s wide range of products and systems used in manufacturing processes and other equipment includes motion control systems, plastics joining, precision cleaning, materials-testing equipment, fluid control valves, alternators, motors, and mechanical power transmission drives and bearings. For information, visit www.emersonindustrialautomation.com.

About Emerson

Emerson (NYSE: EMR), based in St. Louis, Missouri (USA), is a global leader in bringing technology and engineering together to provide innovative solutions for customers in industrial, commercial, and consumer markets through its network power, process management, industrial automation, climate technologies, and tools and storage businesses. Sales in fiscal 2010 were $21 billion. For more information, visit www.Emerson.com.

# # #

Press Contact: Don Goncalves, 781-793-9380, dgoncalves@tizinc.com

Bookmark and Share

Monday, December 6th, 2010

New Low-Power Solenoid Valve Technology Changes the Game for Manufacturers, Assemblers, Engineers: New White Paper Details How

FLORHAM PARK, NEW JERSEY – December 6, 2010 – Process plants worldwide often place considerable reliance on low-power solenoid valves. They are used as pilot valves to open and close larger ball or butterfly valves, or on control valves (installed between positioner and actuator) for fail-safe air release if there’s a loss of power or air. They work by pressurizing or depressurizing associated actuators.

A new white paper from ASCO Numatics, “How New Low-Power Solenoid Valve Technology Changes the Game,” details how a new generation of even lower-power valves is now changing the rules of the power consumption game. These products are of interest to designers working for original equipment manufacturers (OEMs) and valve assemblers, as well as for end-user engineers – anyone who specifies solenoid valves for projects in refining, upstream oil and gas, chemicals, pharmaceuticals and life sciences, food and beverage, and power. The white paper is available free to download at http://www.ascovalve.com.

The white paper taps the expertise of manufacturers at the forefront of low-power solenoid valve technology. It shows how innovation is offering new possibilities – and challenges – via topics such as integrated solutions, clogging and other reliability issues, usefulness in point-to-point and bus networks, other cost savings, remote applications, and relevant industry standards. Finally, it suggests which characteristics buyers should seek out in selecting the newest – and most consistently dependable – low-power valve technologies.

“Choosing low-power solenoid valves for process industry applications presents several challenges. Designers and users must carefully consider such issues as orifice size and clogging potential, pressure rating and other physical characteristics, bus compatibility, backup power needs, and relevant industry standards before selecting the right valve for the given process industry task,” said white paper authors Fabio Okada, Jack Haller, and Manny Arceo – all of ASCO.

Download the new white paper, “How New Low-Power Solenoid Valve Technology Changes the Game,” at http://www.ascovalve.com.

Follow ASCO on Twitter at http://twitter.com/ascovalve. Find ASCO on Facebook at http://www.facebook.com/ascovalve.

About ASCO Numatics

ASCO Numatics, a division of Emerson, offers comprehensive fluid automation solutions, including flow control and pneumatics products, for a wide range of industry-focused applications. The ASCO Numatics product line in North America consists of more than 50,000 valves, an extensive selection of air preparation equipment, and a full line of actuation products. ASCO products include solenoid pilot valves, angle body piston valves, linear indicators, redundant control systems, and pressure sensors. The Numatics line covers valve manifolds, cylinders, grippers, filters, regulators, and lubricators. For more information about ASCO Numatics products, visit http://www.asconumatics.com.

About Emerson

Emerson (NYSE: EMR), based in St. Louis, Missouri (USA), is a global leader in bringing technology and engineering together to provide innovative solutions for customers in industrial, commercial, and consumer markets through its network power, process management, industrial automation, climate technologies, and tools and storage businesses. Sales in fiscal 2010 were $21 billion. For more information, visit http://www.Emerson.com.

# # #

Public Relations contact, Boston:  Don Goncalves, dgoncalves@tizinc.com, 781-793-9380, for Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Bookmark and Share

Wednesday, June 2nd, 2010

New White Paper Helps Medical Device Manufacturers Validate Cleaning Processes

microtest-logo1

AGAWAM, MASS. – June 2, 2010 – A new free, white paper that guides medical device manufacturers in the validation of their cleaning processes is now available from Microtest Laboratories.

As many medical devices are made of high-tech materials such as metallic alloys or synthetic plastics, manufacturers may require the use of various agents to aid in the manufacturing process, or produce contaminants that need to be removed. Thus, these products must be cleaned to ensure both patient safety and the continuing functionality of the device.

In a new white paper titled, “Five Steps to Validating the Cleaning Process of Medical Devices,” Patrick Kenny, Manager of Analytical Services at Microtest Laboratories, reviews medical device regulation under 21 CFR Part 820 – Quality System Regulation. (Download from: http://www.microtestlabs.com/cleaning-validation-paper.)

Several sections of Part 820 can be directly related to device cleanliness. For manufacturers, the challenge is to validate the cleaning process to ensure the devices are free of residue (chemical and particulate) in order to ensure patients are safe.

In the paper, Kenny presents a five-step process that provides a framework to assist medical device manufacturers in their cleaning validation efforts:
• #1: Evaluate the Process, Determine the Potential Contaminants
• #2: Determine the Limits
• #3: Identify the Analytical Test
• #4: Validate the Method for Use
• #5: Validate the Cleaning Process

Download a free copy of “Five Steps to Validating the Cleaning Process of Medical Devices,” from http://www.microtestlabs.com/cleaning-validation-paper.

At Microtest Labs, Kenny leads the services group performing medical device and pharmaceutical analytical testing for companies worldwide. He holds a M.S. degree in Chemistry and has spent the past 13 years working in QC, R&D and manufacturing laboratories.

Follow Microtest Labs on Twitter @MicrotestLabs at http://twitter.com/MicrotestLabs.

About Microtest
Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, U.S.A., the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.

# # #

Public Relations contact, Boston:  Don Goncalves, dgoncalves@tizinc.com, 781-793-9380, for Tiziani Whitmyre Inc., http://www.tizinc.com/public-relations

Bookmark and Share

Tuesday, April 21st, 2009

White Paper Helps Building Owners Minimize Risks and Costs Associated with PCBs in Construction Materials

Needham, Mass. – April 21, 2009 – A new, free white paper can help building owners, developers, and others minimize the very real risks and costs caused by the discovery of PCBs in their construction materials.

The paper titled “What You Need to Know About Managing PCBs in Construction Materials — An Emerging Environmental Issue” details the potential liabilities and current risk management strategies for dealing with polychlorinated biphenyls (PCBs) in construction materials.

“PCB-containing building materials represent a newly discovered and significant liability for building owners, real estate developers, REITS, financing institutions, and contractors, “says John McCarthy, President and co-founder of EH&E Inc., a Needham, Mass.-based environmental services consulting firm.

“The regulation-driven remediation efforts can dramatically impact the cost of renovation or demolition, quickly costing millions of dollars for a single, large-scale project. Public and private owners of real estate must be aware of the regulatory requirements and legal implications. They must have strategies ready to implement to effectively minimize their construction risk and remediation costs,” he said.

The discovery of PCBs in building materials generally occurs once a project has been contracted, resulting in costly project change orders that significantly impact the construction schedule and project costs.

This white paper details a proactive strategy to avoid regulatory mishaps, maintain a safe and healthful building, and accurately assess the need for and costs of any required remediation efforts prior to construction so that these costs can be predicted and minimized in the project budget.

Download the white paper “What You Need to Know About Managing PCBs in Construction Materials—An Emerging Environmental Issue,” at: http://www.eheinc.com/pcbriskmgmt.htm.

Or, for more information contact EH&E directly on the web at: http://www.eheinc.com/ or by phone at: 1-800-825-5343.

About EH&E Inc.
EH&E Inc. (http://www.eheinc.com/) has provided an extensive range of environmental and engineering consulting services for over 20 years. The EH&E team consists of more than 60 experts with an outstanding record of providing business-focused solutions for issues that affect the built environment. EH&E has a depth of knowledge and credibility unmatched in the industry. The firm’s wealth of readily-accessible information is a powerful resource for its clients.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , , ,

Bookmark and Share

Monday, March 16th, 2009

New White Paper Examines Advanced Mycoplasma Tests – How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers

AGAWAM, MASS. – March 16, 2009 – Contamination by mycoplasmal organisms is an ever-present concern in biopharmaceutical manufacturing. Their properties make them ready sources of contamination, while rendering them difficult and time-consuming to detect. A new free white paper, examines how PCR mycoplasma tests and analysis, deployed by a cutting-edge laboratory, minimizes testing delays and enable safe, high-volume biopharmaceutical production.

The new white paper, “Advanced Detection of Mycoplasmas: How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers,” explores relevant mycoplasma characteristics, established testing solutions, and the use of real-time PCR analysis as an alternative testing method for fast, preliminary mycoplasma detection.

It also available for download from: www.microtestlabs.com/mycoplasmapaper.

“Of all the threats that keep quality managers awake at night, mycoplasmas rank high. In a career performing quality control or quality assurance for biopharmaceutical manufacturing anywhere in the world, a QC or QA specialist will probably encounter mycoplasma contamination of a production facility at least once. The resulting devastation to the site’s output and schedules, as well as to its staff’s peace of mind, makes it urgent to avoid any repetition of the experience,” says Dennis Champagne, author of the white paper and Director of Lab Services at Microtest Laboratories, a leader in biopharmaceutical and mycoplasma tests and services.

“Whereas the traditional direct cultivation method takes 28 days to provide results, modern real-time PCR mycoplasma tests and analysis in an experienced testing laboratory may be accomplished in an actual testing duration of only 24 hours, plus the time needed for sample collection, shipment, preparation, and handling,” he said.

The white paper identifies the shortcomings of traditional identification methods, such as direct culture (for cultivable species), indirect culture (DNA fluorochrome staining — for noncultivable species), DNA probe, PCR, enzyme-linked immunosorbent assay (ELISA), autoradiography, and immunofluorescence.

The white paper explains how, as opposed to traditional methods, PCR mycoplasma analysis accurately quantifies DNA and/or RNA, furnishes increased sensitivity and specificity, detects all known mycoplasma species and works whether mycoplasmas in sample are living or dead.

Download the new white paper on PCR mycoplasma tests, “Advanced Detection of Mycoplasms: How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers,” at http://www.microtestlabs.com/mycoplasmapaper.

About Microtest
Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit http://www.microtestlabs.com/ or call 1-413-786-1680 or toll-free 1-800-631-1680.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , ,

Bookmark and Share

Monday, January 12th, 2009

Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers

AGAWAM, MASS. – January 12, 2009 – Two new white papers detailing sterility testing essentials are now available for free download from Microtest (www.microtestlabs.com). The white papers, one which is customized for medical device manufacturers and one which is specialized for pharmaceutical manufacturers, presents the general concepts and problems associated with sterility testing and reviews different testing methodologies.

For medical device manufacturers, sterility testing of medical devices is required during the sterilization process as well as for routine quality control. Understanding sterility testing is essential when designing the validation process. The need to provide adequate and reliable test data is an important quality control issue. False positive results and test failures can have significant impact on production schedules and device time-to market. Medical device manufacturers can download the white paper at: http://www.microtestlabs.com/sterilitypaper/sterility-paper.htm.

For pharmaceutical manufacturers, sterility testing of pharmaceutical articles is an essential element of the sterilization validation process as well as for routine release testing. USP requirements employ sterility testing as an official test to determine suitability of a lot. Understanding sterility testing is beneficial in terms of designing a validation process. In addition, the need to provide adequate and reliable test data is an important quality assurance issue. Pharmaceutical manufacturers can download the white paper at: www.microtestlabs.com/sterilitypaper/pharma-paper.htm.

The author of the white papers is Steven Richter, Ph.D., President and Scientific Founder of Microtest, a leading provider of medical device and pharmaceutical services for medical device designers and manufacturers. The firm recently expanded its facilities, resources, and technology, and with more than 15 years of experience, is a single-source manufacturing solution.

For information on Microtest’s unique single-source solutions that minimize schedule disruptions and accelerate time to revenue visit Microtest on the Web: www.microtestlabs.com or toll-free: 1-800-631-1680.

About Microtest
Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, biotechnology industries. Based in Agawam, Massachusetts, USA, the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.

# # #

Public Relations contact: Tiziani Whitmyre Inc. (http://www.tizinc.com/)

post to del.icio.us

Technorati tags: , , , , , , , ,

Bookmark and Share

Monday, December 1st, 2008

White Paper Addresses FDA Approval Challenges Facing Combination Product Manufacturers

AGAWAM, MASS. – December 1, 2008 – Even as the combination products market continues to experience dramatic growth, the approval process facing manufacturers seeking to introduce new medical devices embedded with pharmaceutical or biologics components is expected to become even more challenging and complex.

“Given the convergence of technologies, combination product manufacturers – often either medical device or pharmaceutical companies “crossing over to the new market” – must ensure their products meet cGMP practices as well as pass muster with the Food and Drug Administration (FDA), the International Organization for Standardization (ISO), and The United States Pharmacopeia (USP),” said Steven Richter, Ph.D., President & Chief Scientific Officer of Microtest Laboratories, and a former FDA official.

“The combination products market is rapidly moving forward with a new direction and emphasis regarding product safety and FDA requirements,” said Richter. “The process, already complex, is likely to become even more so,” he warned.

In fiscal 2007, the FDA received 333 original applications for combination products, a 42 percent increase over 2006. The FDA itself reports that combination product submissions “raise challenging regulatory, policy, and review management issues… (that) can impact the regulatory processes of all aspects of the product life cycle.”

In the free white paper, “Combination Products: Navigating Two FDA Quality Systems,” Richter provides a helpful overview of the challenges facing combination product manufacturers. Download the white paper at www.microtestlabs.com/combinationpaper.

“For manufacturers, the convergence of devices and drugs or biologics brings a host of new FDA testing guidelines, practices, and regulations unique to the development and production of combination products – and generally outside their original core competence in achieving regulatory approvals as either a medical device or pharmaceutical manufacturer,” he said.

In the white paper, Richter discusses: Defining the Convergence, FDA Responsibility, QC Drug Release Criteria, Biologics, New Developments in FDA Thinking, and Future Considerations.

According to the FDA, some estimate the total global value of the drug-device combination products market will grow to $11.5 billion in 2010, up more than double from $5.4 billion in 2004.

Download the free white paper at: www.microtestlabs.com/combinationpaper. For more information, visit Microtest on the Web at www.microtestlabs.com, or call toll-free: 1-800-631-1680.

About Microtest
Microtest is a leader in testing services and contract manufacturing for the medical device, pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts, USA, the company’s expertise and flexible processes enhance product safety and security, accelerate time to market, and minimize supply chain disruption. For more information, visit www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , ,

Bookmark and Share

Tuesday, November 18th, 2008

White Paper Details Infection Control Challenges Hospitals Must Address During Construction Projects

Needham, Massachusetts – November 18, 2008 – Hospitals and healthcare institutions are challenged to devise policies and procedures that allow construction projects to take place while maintaining Environment of Care (EC) standards. A free white paper that addresses these challenges is available for download at: www.eheinc.com/infectioncontrol.htm.

The white paper, titled “Infection Control in the Healthcare Environment During Construction,” details the process required to establish hospital compliance with The Joint Commission (formerly JCAHO) while maintaining a high level of patient care services and critical institution functions.

The white paper will discuss the steps involved in ensuring infection control during hospital construction projects, including how to:

  • Create a construction oversight panel
  • Select which departments and personnel should be on the panel
  • Incorporate Infection Control Risk Assessment (ICRA) elements into construction documents
  • Establish clear-cut project phases.

Authored by Dennis Tremblay, CFPS, a Senior Scientist at EH&E (http://www.eheinc.com/), a Needham, Mass.-based environmental, health, safety, and engineering consulting firm, the white paper is based on the experiences of EH&E personnel while working with leading hospitals and healthcare institutions nationwide.

This white paper reviews the applicable Joint Commission (formerly JCAHO) standards and American Institute of Architects (AIA) guidelines, and describes a field-tested, successful solution for maintaining Infection Control Risk Assessment (ICRA) documentation. The paper will be interesting and informative to all those responsible for maintaining environmental health and safety compliance in hospitals and healthcare facilities.

To download the free white paper, “Infection Control in the Healthcare Environment During Construction,” visit http://www.eheinc.com/infectioncontrol.htm.

EH&E (http://www.eheinc.com/) has provided an extensive range of environmental and engineering consulting services for 20 years. The EH&E team consists of more than 60 experts with an outstanding record of providing business-focused solutions for issues that affect the built environment. EH&E has a depth of knowledge and credibility unmatched in the industry and our wealth of readily-accessible information has become a powerful resource for our clients. EH&E’s new series of EH&E web compliance solutions (http://www.eheinc.com/ehe_web_solutions.htm) is just the latest example of our continuing effort to provide this knowledge and information to a wider range of companies.

# # #

Download public relations images for publication from: http://www.eheinc.com/photos.htm

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/services/public-relations/index.html

bookmark to del.icio.us

Technorati tags: , , , , , , , , ,

Bookmark and Share

Friday, June 20th, 2008

EH&E Launches Interactive Discussion Forum for Healthcare Environment of Care Professionals

Needham, Mass. – June 20, 2008 – EH&E, an environmental and engineering consulting firm for the healthcare industry, has launched “EHEConnect” – an interactive discussion forum dedicated to Environment of Care (EC) professionals – at www.eheconnect.com.

“The forum will act as a central resource for the exchange of ideas and issues central to the mounting, and increasingly complex, responsibilities of those accountable for a healthcare organization’s Environment of Care,” said Kevin Coghlan, M.S., C.I.H, Director of EH&S Compliance & Strategic Support at EH&E. “Our goal is to create a virtual community where EC professionals and others involved in EC issues can login and network with their peers around the country.”

“EHEConnect offers an informal way for EC professionals to exchange ideas, experiences and their solutions to challenges in the EC as well as keep up with The Joint Commission accreditation requirements,” said Coghlan.

EH&E’s team of EC consultants monitor and participate in forum discussions, adding their own professional insights and expertise to the dialogue.

Current topics being discussed include: life safety code documentation; new hospital EtO sterilizer regulations take effect December 2008; OSHA recommendations regarding protection of hospital security personnel in emergences; personal protective equipment for pandemic influenza; extreme temperature policies, interpretation of governing standards for showers and eyewashes.

To learn more and to join EHEConnect, go to: http://www.eheinc.com/forum.htm

EH&E offers a host of customizable services to assist hospitals with a variety of needs including: working to help create a healthy and safe work environment, reducing occupational illness and injury, minimizing workers’ compensation claims, increasing worker morale and productivity, reducing liability, costly litigation and unfavorable publicity, and helping to avoid OSHA fines and other expensive penalties.

About EH&E
EH&E (www.eheinc.com) has provided an extensive range of environmental and engineering consulting services for 20 years. Our team consists of more than 60 experts with an outstanding record of providing business-focused solutions for issues that affect the built environment. EH&E has a depth of knowledge and credibility unmatched in the industry and our wealth of readily-accessible information has become a powerful resource for our clients.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , , ,

Bookmark and Share

Industry PR is proudly powered by WordPress.
WordPress